Google
Trusted Resources: News & Events
Latest announcements and gatherings
Partnership to Ensure Supply of LentiGlobin, Potential Gene Therapy
Bluebird Bio extended a partnership with two divisions of Hitachi Chemical for the long-term development and manufacturing of LentiGlobin, its investigational gene therapy for sickle cell disease (SCD), and other potential and approved treatments.
The two subsidiaries — Hitachi Chemical Advanced Therapeutics Solutions (HCATS) and Apceth Biopharma — will be in charge of late-clinical development and manufacturing of LentiGlobin at facilities in Germany (Apceth) and the U.S. (HCATS).
“It is our honor to support bluebird bio in the manufacture of their potentially transformative gene therapies, to the benefit of patients in both the United States and Europe, as the foundation for our collaboration to address this devastating disease,” Robert Preti, PhD, chief strategy officer at Hitachi Chemical Life Science Business Headquarters, said in a press release.
+myBinderRelated Content
-
10th Annual Sickle Cell Disease Therapeutics Conference – VirtualThe Annual Sickle Cell Disease Therapeut...
-
bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene ...Patient treated with LentiGlobinTM drug ...
-
Walk for Sickle Cell Disease — Greater Boston Sickle Cell Disease AssociationWe take the safety and wellness of each ...
-
2019 Annual Sickle Cell Symposium – Sickle Cell: Past Present and FutureDRAFT Agenda 5:00pm Registration, netwo...
-
Association Between Hospital Admissions and Healthcare Provider Communication for Individuals With Sickle Cell Disea...Objective: To test the hypothesis that ...
-
LentiGlobin Shows Positive Effects in Severe Sickle Cell Disease Patients, Phase 1/2 Data ReportsBluebird bio presented new positive resu...
-
Halloween Health & Safety TipsHalloween is a time for spooky thrills a...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.